TrueWealth Advisors LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 60.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,767 shares of the company’s stock after purchasing an additional 665 shares during the quarter. TrueWealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,364,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Retirement Wealth Solutions LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $119,000. 25 LLC increased its stake in shares of Eli Lilly and Company by 17.8% during the 4th quarter. 25 LLC now owns 305 shares of the company’s stock worth $235,000 after purchasing an additional 46 shares during the last quarter. Merit Financial Group LLC raised its holdings in shares of Eli Lilly and Company by 44.3% in the 4th quarter. Merit Financial Group LLC now owns 20,551 shares of the company’s stock valued at $15,865,000 after purchasing an additional 6,307 shares during the period. Boston Common Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 29.4% in the 4th quarter. Boston Common Asset Management LLC now owns 24,028 shares of the company’s stock valued at $18,550,000 after purchasing an additional 5,465 shares during the period. Finally, Relyea Zuckerberg Hanson LLC lifted its stake in Eli Lilly and Company by 11.9% in the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,033 shares of the company’s stock valued at $2,342,000 after purchasing an additional 323 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.
Analysts Set New Price Targets
Several analysts have issued reports on LLY shares. Barclays dropped their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target for the company. Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Bank of America reissued a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.
Insider Activity at Eli Lilly and Company
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by insiders.
Eli Lilly and Company Stock Performance
NYSE LLY opened at $726.24 on Friday. The firm’s 50 day simple moving average is $781.14 and its 200 day simple moving average is $854.71. The firm has a market capitalization of $689.43 billion, a price-to-earnings ratio of 78.51, a P/E/G ratio of 1.66 and a beta of 0.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1 year low of $612.70 and a 1 year high of $972.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 13.14 earnings per share for the current fiscal year.
Eli Lilly and Company Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.
Eli Lilly and Company announced that its board has authorized a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Ride Out The Recession With These Dividend Kings
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 01/13 – 01/17
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.